https://ipharmag.com/article/vitestro-aletta-robotic-blood-draw-fda-authorization iPharmag en 2026-08-20T11:42:58+00:00 FDA Clears the First Robotic Blood-Draw Device That Works on Its Own https://ipharmag.com/article/ultragenyx-genglycos-gene-therapy-gsd1a-approval iPharmag en 2026-08-20T11:42:58+00:00 First Gene Therapy for a Rare Metabolic Disease Wins Accelerated FDA Approval https://ipharmag.com/article/regeneron-pasatru-fop-stone-man-disease-fda-approval iPharmag en 2026-08-20T11:42:58+00:00 FDA Approves Regeneron’s Pasatru for Ultra-Rare ‘Stone Man Disease’ https://ipharmag.com/article/kynexis-97m-schizophrenia-cognition-kyn5356 iPharmag en 2026-08-20T11:42:58+00:00 Kynexis Raises €97M to Chase a Hard Target: The Cognitive Symptoms of Schizophrenia https://ipharmag.com/article/ai-designed-intrabodies-neurodegeneration iPharmag en 2026-08-20T11:42:58+00:00 AI-Designed ‘Intrabodies’ Could Open a New Route to Treating Brain Diseases https://ipharmag.com/article/moderna-merck-mrna-melanoma-vaccine-phase-3-interpath iPharmag en 2026-08-19T12:18:48+00:00 Moderna and Merck’s mRNA Cancer Vaccine Succeeds in Landmark Phase 3 Melanoma Trial https://ipharmag.com/article/faeth-piktor-paclitaxel-fda-fast-track-endometrial-cancer iPharmag en 2026-08-19T12:18:48+00:00 FDA Grants Fast Track to Faeth’s Metabolic Cancer Combo for Advanced Endometrial Cancer https://ipharmag.com/article/blood-pressure-ccb-kidney-risk-type-2-diabetes iPharmag en 2026-08-19T12:18:48+00:00 A Common Blood-Pressure Drug Class Is Linked to Higher Kidney Risk in Type 2 Diabetes, Study Finds https://ipharmag.com/article/astrazeneca-tagrisso-saffron-egfr-met-lung-cancer iPharmag en 2026-08-19T12:18:48+00:00 AstraZeneca’s Tagrisso Combo Extends Survival in Hard-to-Treat Lung Cancer https://ipharmag.com/article/amylyx-avexitide-glp1-blocker-post-bariatric-hypoglycemia iPharmag en 2026-08-19T12:18:48+00:00 Amylyx’s Bet on a GLP-1 ‘Blocker’ Pays Off in Post-Surgery Low Blood Sugar